Zhongnan Medical Journal Press

Home Results

A total of 15 result was found. Results that relate to Liver disease

Prevalence and influencing factors of MAFLD among residents aged 65 years and older in a district of Wuhan

Published on New Medicine 2022,32(1):120-126.
11707 times 3538 times

Wen-Shuang WEI Fang LI Ya-Qiong YAN Yan GUO Qing LIU

Metabolic associated fatty liver disease MAFLD Prevalence Influencing factors
Details
Polyene phosphatidylcholine injection in the treatment of alcoholic liver disease: a systematic review and Meta-analysis

Published on Frontiers in Pharmaceutical Sciences 2024,27(1):135-144.
6599 times 1497 times

ZENG Baoqi ZHANG Meng LIU Xiaozhi SHENG Feng SUN Feng

Polyene phosphatidylcholine Alcoholic liver disease Efficacy Meta-analysis Randomized controlled trial
Details
Advances in non-invasive diagnosis of metabolic dysfunction-associated fatty liver disease

Published on New Medicine 2024,34(7):807-816.
7272 times 1701 times

WANG Ziqian WANG Shixu LIU Yihang WANG Chaoyang

Metabolic dysfunction-associated steatotic liver disease Metabolic dysfunction-associated steatohepatitis Hepatic steatosis Liver fibrosis Serum biomarker Diagnosis
Details
A two-sample bidirectional Mendelian randomization study of the causality between autoimmune liver disease and diabetes mellitus

Published on Journal of Mathematical Medicine 2024,37(7):481-489.
8163 times 1491 times

LIN Menglu CHENG Jie HU Fan FENG Jiahui CHEN Xiaojia Tannuer·MAIMAITIAISHAN CHENG Yan LIN Jun

Autoimmune liver disease Diabetes mellitus Mendelian randomization Causality
Details
Evaluation of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease using ultrasound controlled attenuation parameter combined with clinical features

Published on New Medicine 2024,34(10):1121-1129.
5982 times 1558 times

LIU Chunyu TANG Jingkuan ZHAO Wei

Metabolic dysfunction-associated steatotic liver disease Liver fibrosis Ultrasound Controlled attenuation parameter Machine learning Diagnose
Details
Exploration of the pharmacodynamic substance basis and mechanism of Honghua Qinggan Shisanwei pills in treating non-alcoholic fatty liver based on HPLC-Q-Exactive MS and network pharmacology

Published on Frontiers in Pharmaceutical Sciences 2024,28(3):365-380.
6319 times 1181 times

HAO Xia LIU Jing ZHANG Qian LI Jun

Honghua Qinggan Shisanwei pills Non-alcoholic fatty liver disease High performance liquid chromatography-Q-Exactive mass spectrometry Network pharmacology Molecular docking Insulin resistance Oxidative stress
Details
Prevalence and risk factors of nonalcoholic fatty liver disease in overweight and obese children: a Meta-analysis

Published on Journal of Mathematical Medicine 2024,37(12):935-946.
8425 times 1084 times

XIANG Feng CAO Xuehua HU Wanqin JIA Yu

Nonalcoholic fatty liver disease Overweight Obese Children Incidence Body mass index Meta-analysis
Details
Construction and validation of the diagnostic model for metabolic dysfunction-associated steatotic liver disease among the non-obese population

Published on New Medicine 2025,35(2):141-150.
6472 times 1325 times

WANG Yufeng HU Minxuan LI Yuntao ZHU Kexin JI Guozhong YUAN Yuan

Metabolic dysfunction-associated steatotic liver disease Non-obese Diagnostic model Logistic regression Predictive model
Details
Mendelian randomization and bioinformatics analysis of TRIM31 with chronic liver disease

Published on New Medicine 2025,35(3):303-311.
4292 times 1093 times

YOU Junyi LIANG Guoqiang SONG Xiudao

Mendelian randomization Tripartite motif 31 Chronic liver disease Hepatocellular carcinoma Bioinformatics
Details
Effectiveness of different immunonutrients in the treatment of nonalcoholic fatty liver disease: a network Meta-analysis

Published on Journal of Mathematical Medicine 2025,38(3):214-224.
5290 times 948 times

LYU Jie MA Li ZHANG Qian SUN Shuxin JIA Yatian ZHANG Yihua

Immunonutrient Nonalcoholic fatty liver disease Curative effect Network Meta-analysis
Details
Research progress on the hepatoprotective mechanism of Berberis and its active components

Published on Frontiers in Pharmaceutical Sciences 2025,29(5):832-848.
5610 times 840 times

YANG Guibin GUI Mingan GUO Hao ZHUOMA Dongzhi YUAN Ruiying

Berberis Active ingredient Liver disease Hepatoprotective effect
Details
Research progress on the role and mechanism of Chitooligosaccharides in improving metabolic dysfunction-associated fatty liver disease

Published on Frontiers in Pharmaceutical Sciences 2025,29(8):1422-1430.
2424 times 410 times

ZHONG Li HUANG Guidong

Chitooligosaccharides Metabolic dysfunction-associated fatty liver disease Lipid-Lowering mechanism Research progress
Details
Effect of regulating miR-29b-3p/FoxO3 axis by asiaticoside on alleviating liver injury in rats with non-alcoholic fatty liver disease

Published on New Medicine 2025,35(10):1165-1172.
777 times 261 times

TAN Jie LIU Meng TIAN Xia HAN Zheng ZHU Qingxi ZHAN Ting CHEN Mingtao CHEN Aifang HUANG Min

Asiaticoside Non-alcoholic fatty liver disease Liver injury MicroRNA-29b-3p/forkhead box O3
Details
Systematic biological study on traditional Chinese medicine treatment for non-alcoholic fatty liver disease: analysis of compatibility patterns and multi-target synergistic mechanisms

Published on Frontiers in Pharmaceutical Sciences 2025,29(11):1878-1886.
1221 times 165 times

ZHANG Zhenwei ZHANG Nana ZHANG Hua SHI Lei YU Qiuxiang

Non-alcoholic fatty liver disease Network pharmacology Molecular mechanism Chemical components of traditional Chinese medicine Collaborative efficiency enhancement
Details
Association of sleep duration and sleep quality with metabolic associated fatty liver disease among Wuhan subway workers

Published on New Medicine 2025,35(11):1256-1264.
336 times 118 times

PENG Rong LIU Junling SHI Bin TAO Yi YAN Xueping HE Zhenyu

Sleep duration Sleep quality Metabolic associated fatty liver disease Mediation effect
Details